v3.24.2.u1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Revenues        
Services $ 116,090 $ 50,163 $ 155,866 $ 55,519
Product 279,707 166,147 411,466 310,599
Total Revenues 395,797 216,310 567,332 366,118
Operating Expenses        
Research and development 3,715,797 5,451,287 8,345,324 10,356,965
General and administrative 2,284,041 2,644,957 4,537,784 5,226,660
Sales and marketing 1,386,378 1,669,102 3,059,147 3,376,559
Total Operating Expenses 7,386,216 9,765,346 15,942,255 18,960,184
Operating Loss (6,990,419) (9,549,036) (15,374,923) (18,594,066)
Other Income (Expenses)        
Grant income 0 0 0 165,795
Loss on disposal of fixed assets (33,498) 0 (33,498) 0
Interest income 450 27,109 9,104 84,757
Interest expense (81,182) (58,321) (158,415) (109,643)
Gain on change in fair value of warrant liability 44,474 28,971 25,552 28,971
Total Other Income (Expenses) (69,756) (2,241) (157,257) 169,880
Net Loss (7,060,175) (9,551,277) (15,532,180) (18,424,186)
Net Loss Attributable to Non-Controlling Interest 74,629 80,298 179,246 173,659
Net Loss Attributable to VolitionRx Limited Stockholders (6,985,546) (9,470,979) (15,352,934) (18,250,527)
Other Comprehensive Income (Loss)        
Foreign currency translation adjustments 23,286 37,712 38,312 (18,766)
Net Comprehensive Loss $ (7,036,889) $ (9,513,565) $ (15,493,868) $ (18,442,952)
Net Loss Per Share - Basic and Diluted Attributable to VolitionRx Limited $ (0.08) $ (0.14) $ (0.19) $ (0.29)
Weighted Average Shares Outstanding - Basic and Diluted 82,669,335 66,884,368 82,312,161 63,613,224

Source

10-Q PDF
XBRL